AcquisitionAug 18, 2026Pending
🇺🇸 United States
ATAlesta TherapeuticsBPBioMarin Pharmaceutical Inc.
Healthcare › Biotechnology
Equity value$275MEquity value
AnnouncedAug 18, 2026
ConsiderationCash
StructureOther
RegionNorth America
Cross-borderNo
Contingent paymentYes
Overview
BioMarin agreed to acquire Alesta Therapeutics, gaining its clinical-stage oral hypophosphatasia asset ALE1, after Alesta spins out all non-ALE1 assets. Alesta shareholders receive $275 million upfront plus up to $215 million in development and regulatory milestone payments.
Deal rationale
ALE1 is a potential first oral therapy for hypophosphatasia that strengthens BioMarin's early-stage clinical pipeline and lets it compete in larger rare disease markets.
AI-generated from the SEC filingPendingHealthcare › BiotechnologyUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | $275M | Headline figure |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Cash |
Advisors
Buy-side
MSMorgan Stanley
Sell-side
JPJ.P. Morgan
Parties
Target
ATAlesta Therapeutics
- Headquarters
- United States
- Ticker
- —